Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visx/Alcon Laboratories

This article was originally published in The Gray Sheet

Executive Summary

Firms sign letter of intent under which Visx "for a negotiated fee" will make use of Alcon's "resources and expertise" to guide a voluntary review of Visx clinical investigative sites. FDA recently sent Form 483 inspectional observation reports to two of Visx's 26 investigative sites ("The Gray Sheet" Sept. 12, p. 13). However, Visx maintains that its decision to conduct the independent reviews "was neither requested nor required by the FDA." The agreement also calls for Alcon to provide further "regulatory services" to Visx "on an ongoing basis." In addition, Visx announces that Alcon Chairman, CEO and President Edgar Schollmaier will rejoin Visx' board of directors; Schollmaier served on the Visx board from 1987 to 1993

You may also be interested in...



EMA Stands By Suspension Of Ranitidine In EU After Re-Examination

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate

Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel